Curanex Pharmaceuticals Inc Common Stock (CURX) Stock Analysis

What Curanex Pharmaceuticals Inc Common Stock does

Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.

Key metrics

ETFs linked to CURX

Broad-market and Healthcare sector ETFs an investor holding Curanex Pharmaceuticals Inc Common Stock is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CURX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Curanex Pharmaceuticals Inc Common Stock?

Curanex Pharmaceuticals Inc Common Stock trades under the ticker CURX on NASDAQ.

Which exchange is CURX listed on?

CURX is listed on NASDAQ.

What sector does Curanex Pharmaceuticals Inc Common Stock operate in?

Curanex Pharmaceuticals Inc Common Stock is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CURX in a portfolio?

PortView shows CURX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.